Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Other Events

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Other Events

Story continues below

Item8.01

Other Events.

On June24, 2017, Agios Pharmaceuticals, Inc. (the Company) issued
a press release announcing updated clinical data from the
Companys ongoing phase 2 DRIVE PK study evaluating AG-348 in
patients with pyruvate kinase deficiency. Also on June24, 2017,
the Company issued a press release announcing new efficacy and
safety data from the ongoing Phase 1/2 dose-escalation and
expansion study evaluating investigational oral IDHIFA
(enasidenib) in patients with relapsed or refractory acute
myeloid leukemia with an isocitrate dehydrogenase-2 mutation.
These data were presented at the 22nd Congress of the European
Hematology Association (EHA) taking place June 22-25, 2017 in Madrid,
Spain.

The full text of
the press releases issued in connection with these announcements
are attached as Exhibit 99.1 and Exhibit 99.2 to this Current
Report on Form 8-K and incorporated herein by reference.


Item9.01
Financial Statements and Exhibits.

(d) The following
exhibits are included in this report:


Exhibit


No.


Description

99.1 Press release issued by Agios Pharmaceuticals, Inc. on
June24, 2017.
99.2 Press release issued by Agios Pharmaceuticals, Inc. on
June24, 2017.



AGIOS PHARMACEUTICALS INC Exhibit
EX-99.1 2 d377410dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency – AG-348 Is Well-Tolerated and Demonstrates Clinically Relevant,…
To view the full exhibit click here
About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.

An ad to help with our costs